Dr Bill Love, CEO of Destiny Pharma commented: "Progression into Part 2 of this important US clinical trial for XF-73 is a significant milestone. The new clinical guidelines underline the need for new therapies that are not associated with a risk of resistance development, something that we obviously believe XF-73 will be able to provide."
XF-73 is a novel dicationic porphyrin with rapid bactericidal activity against Gram-positive bacteria including Staphylococcus aureus (methicillin sensitive and multi-drug resistant strains including MRSA).
2. Noskin GA, et al. National trends in Staphylococcus aureus infection rates. Impact on economic burden and mortality over a 6 year period (1998 -2003). Clinical Infectious Disease, (2007), 45, 1132-40.
3. Bratzler et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. Am J Health Syst Pharm, (2013),70,195-283 http://www.ashp.org/DocLibrary/BestPractices/TGSurgery.aspx.
4. Farrell D, et al. Investigation of the Potential for Mutational Resistance to XF-73, Retapamulin, Mupirocin, Fusidic Acid, Daptomycin, and Vancomycin in Methicillin-Resistant Staphylococcus aureus Isolates during a 55-Passage Study. Antimicrobial Agents and Chemotherapy, (2011), 55, (3), 1177-81
About Destiny Pharma:
Destiny Pharma, a clinical stage pharmaceutical company, was founded in 1997. The Company focuses on the R&D of new antimicrobial drugs, with an emphasis on novel mechanisms of action which seek to address a top 3 global healthcare issue, namely, microbial drug resistance. XF-73 is the Company's lead drug which has completed Phase I clinical development in the UK. Through its extensive business network and strategic partnerships, Destiny Pharma intends to globally commercialise candidates from the XF Drug platform which are differentiated by design from traditional antibiotics.
About the NIH and NIAID:
NIH, the U.S. medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research-at NIH, within the U.S. and worldwide-to study the causes of infections and immune-mediated diseases and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website at www.niaid.nih.gov.
Forward Looking Statement:
This press release contains forward looking statements that are subject to risks and uncertainties and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Destiny Pharma disclaims any intent or obligation to update forward looking statements except as required by law.
For further information about NIAID, visit www.niaid.nih.gov.
+44 1273 704440
Most Popular Stories
- 15 Myths That Could Ruin Your Hispanic Ad Campaign
- Bitcoin Clones Lurch Onto Financial Scene
- General Motors Names Mary Barra as First Female CEO
- AIG to Create 230 Jobs in Charlotte
- Clinton to Keynote Annual Simmons Leadership Conference
- How Bitcoin and Other Cryptocurrencies Work
- Californians Want to Legalize Marijuana
- Pacific Trade Pact Delay Hinders U.S. Pivot to Asia
- Budget Deal Sets Off Grumbles in Both Houses
- Russia Says Nyet to Canada North Pole Claim